|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 17, 2019 ) The Indian Heparin Market is projected to reach USD 883.0 million and USD 170.2 million by 2022, respectively.
The Indian peptide drugs market is projected to reach USD 883.0 million by 2022 from USD 381.8 million in 2016, at a CAGR of 15.0%. Increasing prevalence of chronic diseases such as cancer and diabetes and favorable government policies for the pharmaceutical sector are the major factors driving the growth of Indian peptide market.
The Indian anticoagulant drugs market to reach USD 170.2 million in 2022 from USD 127.8 million in 2016 and is expected to register a CAGR of 4.9%. Factors such as incidence of coagulation disorders and government support for pharmaceutical companies are contributing to the growth of this market.
To know about the assumptions considered for the study download the pdf brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77044734
“By type, hormonal segment is expected to dominate the market in 2016”
On the basis of type segmentation, The Indian peptide drugs market is classified into hormonal, antifungal, antibiotic, ACE inhibitor and others. The hormonal segment is expected to dominate the Indian peptide drugs market in 2016. Growing incidence and prevalence rate of diabetes in India and rising ageing population are the major driving factors for this segment.
“By application, the diabetes segment is expected to dominate the market in 2016”
Based on application, the indian peptide drugs market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological application, and other applications. In 2016, the diabetes segment is expected to account for the largest share of the Indian peptide drugs market, by application. The growth in the segment can be primarily attributed to increasing incidence and prevalence of diabetes cases in the country.
"By type, Enoxaparin sodiumsegment is expected to dominate the market in 2016"
On the basis of Low molecular weight heparin type, the Indian anticoagulant drugs market is classified into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. In 2016, the enoxaparin sodium segment is expected to account for the largest share of the Indian anticoagulant drugs market, by type.
For More Details, Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=77044734
MarketsandMarkets™
Mr. Shelly Singh
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
